- Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenueCNBC
- Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance | Eli Lilly and CompanyInvestors | Eli Lilly and Company
- Eli Lilly Stock Rises on Earnings Beat, Obesity Drug SalesBarron’s
- Live news: Eli Lilly says diabetes and obesity drugs will boost sales by 20% this yearFinancial Times
- Eli Lilly mounts clinical and commercial case for tirzepatide as Mounjaro, Zepbound chalk up major gainsFiercePharma